Understanding the New Multimodality Prognostic Score (MMPS) in Mesothelioma

Understanding the New Multimodality Prognostic Score (MMPS) in Mesothelioma

The Multimodality Prognostic Score (MMPS) is a new tool for evidence-based mesothelioma treatment. It has given clinicians and surgeons a new guideline in multimodality treatment. The treatment options for mesothelioma are many. Often, one treatment alone cannot control cancer so many treatment types are required. Multimodal therapy can be tailored to each patient’s case. The Multimodality Prognostic Score (MMPS) has an update. It is a tool in the clinician’s toolbox for outlining a treatment plan. Surgical Options Surgery is a common treatment option for malignant pleural mesothelioma. There are two surgeries that are most common. The first is pleurectomy and decortication (P/D) surgery. The second is an extrapleural pneumonectomy (EPP). Pleurectomy and decortication surgery (P/D) is a common pleural mesothelioma … Continue reading Understanding the New Multimodality Prognostic Score (MMPS) in Mesothelioma »

Treatment Combination for Younger Pre-Treated Mesothelioma Patients

Treatment Combination for Younger Pre-Treated Mesothelioma Patients

There are many systemic therapies recommended for mesothelioma patients. Different therapies may work best for different patient populations. Different therapies may work better for older versus younger patients. Or, patients who have received treatment before. An international team of clinicians published a new study on this topic. They found a treatment strategy that works best for younger pre-treated patients. The Young (65 years or younger) and Pre-Treated Patient Mesothelioma patients who have received treatment once before, are often called “pre-treated.” Clinicians often have more personalized data available for these patients. This affects the clinician’s treatment strategy. A new study compared the data from nine different mesothelioma clinical trials. These clinical trials spanned standard and experimental treatment options. The results are … Continue reading Treatment Combination for Younger Pre-Treated Mesothelioma Patients »

New Drug Targeting Fibrosis may Help Mesothelioma Patients

Targeting Fibrosis in Mesothelioma has Therapeutic Benefits

Targeting fibrosis has therapeutic benefits in mesothelioma. Most drugs have limited effects in difficult-to-treat cancers such as mesothelioma. Often this is because not enough of the drug can get into the tumor to generate an anti-tumor effect. Fibrosis is a common element of mesothelioma. It causes the area around the cancer to stiffen. Fibrosis acts as a barrier, stopping drugs from getting into the cancer tumor. This limits the immune system’s ability to detect and access the tumor to kill it. A new study is looking at how a family of proteins called lysyl oxidases can help solve this problem. These proteins are associated with fibrosis in many cancers, including mesothelioma. Oncologists targeting fibrosis and this protein family may improve … Continue reading New Drug Targeting Fibrosis may Help Mesothelioma Patients »

Top Three Factors Predicting Mesothelioma Survival are Age, Histological Type, and Surgery Status

Top Three Factors Predicting Mesothelioma Survival

Malignant pleural mesothelioma is a rare and aggressive malignancy with a dismal prognosis. A new study is predicting mesothelioma survival among male and female patients in the United States. Identifying factors “associated with mesothelioma mortality is important research given the poor prognosis” according to Dr. Bian Liu from the a Icahn School of Medicine at Mount Sinai in New York. A new study applied a machine-learning algorithm to 12,210 patients to predict survival. The top three factors were age, histological type, and cancer-directed surgery status. Analyzing Over 12,000 Mesothelioma Patients Scientists from the New York State Department of Health included 12,210 mesothelioma patients. They involved only malignant pleural mesothelioma patients. They excluded cases with unknown diagnostic confirmation and unknown survival … Continue reading Top Three Factors Predicting Mesothelioma Survival are Age, Histological Type, and Surgery Status »

How To Get Mesothelioma Compensation Even If You Were Born Outside The US… Or Other Law Firms Turned You Down

When first diagnosed with Mesothelioma, many people from other countries are surprised to learn that their case is rejected by a law firm. This is because compensation is mostly available to people who lived and worked in the United States and were exposed to asbestos there.    Luckily, there are other options available to help you get compensated. Here are some ways you can apply for Mesothelioma compensation even if you were born outside the US.   Why isn’t Mesothelioma compensation available for everyone? Many law firms in the US will not help foreign mesothelioma patients. One reason is because there is a lot more work involved when trying to get compensation for people who were born overseas. In addition, if … Continue reading How To Get Mesothelioma Compensation Even If You Were Born Outside The US… Or Other Law Firms Turned You Down »

Historic Timeline of Asbestos Exposure in Denmark: Predicting the Next Decade

Historic Timeline of Asbestos Exposure in Denmark

A historic timeline of asbestos exposure in Denmark has been created. This is the first known attempt to compile asbestos measurements in Danish workplaces. The Danish National Research Centre for the Working Environment released a new report. It indicates that historical asbestos exposure measurements are valuable for current risk assessment. Asbestos Measurements and Concentrations This work shows the airborne fiber concentration ranges in specific work tasks. And it is divided into different industries over time. The historical asbestos exposure database contained 9,236 records. Of these, 5,869 data entries contained high-quality measurements of asbestos concentrations. The database includes data from 1971 to 1997. These historic reports can identify specific work scenarios with high asbestos exposures. There had not been any previous … Continue reading Historic Timeline of Asbestos Exposure in Denmark: Predicting the Next Decade »

Lung-Sparing Surgery and Mesothelioma Survival

lung-sparing surgery

Italian researchers say lung-sparing surgery can lead to long-term mesothelioma survival, even if surgeons take a more conservative approach.  Lung-sparing surgery for mesothelioma is also known as pleurectomy with decortication (P/D). P/D surgery is less extensive than the other main surgical approach for mesothelioma but it is also less risky. Now, doctors at Venice-Mestre Hospital say that, as long as it is performed early enough and combined with other treatments, lung-sparing surgery saves lives. Their report in the Journal of Thoracic Disease details the outcomes of 155 mesothelioma surgery patients tracked for a median of a year-and-a-half.  Extrapleural Pneumonectomy & Lung-Sparing Surgery Extrapleural pneumonectomy (EPP) is the most radical operation for pleural mesothelioma. In addition to removing the mesothelioma tumor … Continue reading Lung-Sparing Surgery and Mesothelioma Survival »

Artificial Intelligence Tool Measures Mesothelioma Treatment Response

artificial intelligence tool

Scientists at the University of Glasgow in Scotland have developed an artificial intelligence tool that could revolutionize the way doctors plan and monitor mesothelioma treatment.  The University team collaborated with Scottish firm Canon Medical Research Europe to develop an AI prototype for detecting pleural mesothelioma. Canon Medical specializes in medical imaging software.  Pleural mesothelioma is a type of lung cancer caused by asbestos exposure. The new artificial intelligence tool is designed to find and measure mesothelioma tumors on CT scans.  It can be challenging even for cancer experts to detect tiny changes in mesothelioma tumors. But the AI tool can quickly reveal how well or poorly a patient is doing on a treatment like chemotherapy. The sooner doctors know if … Continue reading Artificial Intelligence Tool Measures Mesothelioma Treatment Response »

Chemotherapy Spray Could Make Surgery Possible for More Peritoneal Mesothelioma Patients

chemotherapy spray

A technique that turns anti-cancer drugs into a chemotherapy spray could be a breakthrough for some peritoneal mesothelioma patients who were told they were not candidates for surgery.  The procedure is called PIPAC. It stands for pressurized intraperitoneal aerosol chemotherapy. It allows doctors to apply cancer-killing medication directly to the site of peritoneal mesothelioma tumors.  A new French study suggests that the chemotherapy spray, in combination with systemic chemotherapy, can shrink some tumors enough to completely remove them – even if doctors did not initially think resection was possible.  The study tracked several cases of successful surgery after standard chemotherapy and PIPAC. The retrospective study shows patients who had surgery experienced much longer progression-free survival than those who did not.  … Continue reading Chemotherapy Spray Could Make Surgery Possible for More Peritoneal Mesothelioma Patients »

New Mesothelioma Trial to Test Tri-Modal Approach

new mesothelioma trial

Enrollment is open for a new mesothelioma trial run by Memorial Sloan Kettering Cancer Center to test a three-prong approach to treatment.  Pleural mesothelioma is a lung-related cancer caused by asbestos. It is notoriously difficult to treat and highly aggressive.  The new mesothelioma trial aims to recruit 150 pleural mesothelioma patients. Patients will receive lung-sparing surgery and chemotherapy. Some will also receive intensity modulated radiation therapy (IMRT).  Researchers will test which group does better – those who only have surgery and chemotherapy or those who also have targeted radiation therapy. They plan to measure not only survival but also complications, quality of life, and how long it takes for the cancer to come back.  Tri-Modal Treatment to Fight Mesothelioma The … Continue reading New Mesothelioma Trial to Test Tri-Modal Approach »

Get your free copy of
“Surviving Mesothelioma” Today!